Fill in the email address of your friend, and we will send an email
that contains a link to this page.
About the Authors
Tom Keelin headed SDG's pharmaceutical practice at the time he wrote this article. Dr. Keelin is now managing director of Keelin-Reeds Partners.
Paul Sharpe, now retired, was vice president and director of project management in neuroscience at SmithKline Beecham at the time he wrote this article.
